Stay updated with breaking news from Philippe Barth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First patient to be administered Oncobax® AK, a live bacterial product based on a specific strain found in the gut microbiota, at Institut de Cancérologie Strasbourg Europe (ICANS) in Strasbourg, France60 patients across France and Belgium to take part in a trial which aims to assess the toxicity and efficacy of the...
Taking into account Artmarket.com's shareholder equity, equity of the market, and their access to any information likely to impact the share price, Artmarket.com must inform the market and its shareholders
email article Cabozantinib (Cabometyx) came out on top as upfront therapy in metastatic papillary renal cell carcinoma (RCC) in a randomized phase II study. Treatment with the multikinase inhibitor yielded a median progression-free survival (PFS) of 9.0 months, as compared to 5.6 months with sunitinib (Sutent), which has been the default standard of care in this setting (HR 0.60, 95% CI 0.37-0.97, one-sided P=0.019), reported Sumanta Pal, MD, of City of Hope Comprehensive Cancer Center in Duarte, California. Overall response rate was significantly improved with cabozantinib compared wi...